Accordingly, anemia in patients with advanced CKD was targeted with EPO or erythropoiesis-stimulating agents (ESAs) (Eschbach et al., 1987), along with oral or intravenous iron supplementation (Gafter-Gvili et al., 2019; Batchelor et al., 2020). This evidence concerns the gene EPO and chronic kidney disease.